Q-omics provides the consensus-scored FTLP4 profile across patient tissues and cancer cell-line models. FTLP4 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FTLP4 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, FTLP4 RNA expression shows 4,724 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, COAD, and STAD as cancer lineages where FTLP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP4 survival associations across molecular data types. FTLP4 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP4 RNA expression–survival associations across cancer types. High FTLP4 expression shows unfavorable associations in ACC, KICH, THCA and KIRP, but favorable associations in LUAD and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FTLP4 RNA expression.
This table summarizes FTLP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP4 shows lower tumor expression in LUAD and higher tumor expression in COAD. The COAD box plot shows higher FTLP4 RNA expression in tumor versus normal tissue (log2 FC = +0.059, t-test p = .042).
This table shows molecular features associated with FTLP4 in patient tissues and cancer cell lines. In patient samples, FTLP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
